Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes Mellitus
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 239,990
- 试验地点
- 1
- 主要终点
- 3-point MACE
研究概览
简要总结
Replication of three clinical trial emulations CANVAS, LEADER, and SAVOR TIMI that form part of the RCT-Duplicate initiative, sponsored by the FDA and delivered by the Brigham and Women's Hospital and Harvard Medical School. AstraZeneca will use the Instant Health Data platform PANALGOS (IHD) for the analyses.
详细描述
RCT-duplicate (RCT-D) is an initiative led by the Brigham and Women's Hospital and Harvard Medical School, that selected 30 clinical trials as part of an empirical experiment where these trials would be emulated using RWD. AstraZeneca will replicate three emulations CANVAS, LEADER, and SAVOR TIMI from among the 30 plus clinical trials analyzed in RCT-D. These clinical trials assess type 2 diabetes mellitus drugs. The replications will be conducted on the Instant Health Data PANALGOS (IHD) platform to assess these studies in two claims databases Optum and IBM Watson Market Scan. The aim is to recreate these three emulations to investigate the reproducibility of the emulations, increase transparency and better understand the process of trial emulations; and where possible, contribute with potential improvements to the RCT-D framework.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
CANVAS Canagliflozin
CANVAS expousre Group
干预措施: Canagliflozin (Drug)
CANVAS DPP4i
CANVAS reference Group
干预措施: DPP4 inhibitor (Drug)
LEADER Liraglutide
LEADER exposure Group
干预措施: Liraglutide (Drug)
LEADER DPP4i
LEADER reference Group
干预措施: DPP4 inhibitor (Drug)
SAVOR-TIMI Saxagliptin
SAVOR-TIMI exposure Group
干预措施: Saxagliptin (Drug)
SAVOR-TIMI 2nd generation Sulfonylurea
SAVOR-TIMI reference Group
干预措施: 2nd generation Sulfonylurea (Drug)
结局指标
主要结局
3-point MACE
时间窗: Follow up begins the day after drug initiation for the three investigated studies [a median of 134-167 days]
3-point MACE: Relative hazard of composite outcome of Stroke, MI, and Mortality
次要结局
未报告次要终点
